GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Interest Coverage

CPMV (Mosaic ImmunoEngineering) Interest Coverage : 0 (At Loss) (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Mosaic ImmunoEngineering's Operating Income for the three months ended in Sep. 2024 was $-0.19 Mil. Mosaic ImmunoEngineering's Interest Expense for the three months ended in Sep. 2024 was $-0.02 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Mosaic ImmunoEngineering's Interest Coverage or its related term are showing as below:


CPMV's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 132.23
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Mosaic ImmunoEngineering Interest Coverage Historical Data

The historical data trend for Mosaic ImmunoEngineering's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mosaic ImmunoEngineering Interest Coverage Chart

Mosaic ImmunoEngineering Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt - - -

Mosaic ImmunoEngineering Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mosaic ImmunoEngineering's Interest Coverage

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Interest Coverage falls into.



Mosaic ImmunoEngineering Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mosaic ImmunoEngineering's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Mosaic ImmunoEngineering's Interest Expense was $-0.09 Mil. Its Operating Income was $-1.40 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.32 Mil.

Mosaic ImmunoEngineering did not have earnings to cover the interest expense.

Mosaic ImmunoEngineering's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Mosaic ImmunoEngineering's Interest Expense was $-0.02 Mil. Its Operating Income was $-0.19 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.37 Mil.

Mosaic ImmunoEngineering did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Mosaic ImmunoEngineering Interest Coverage Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering Business Description

Traded in Other Exchanges
N/A
Address
9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering Headlines

From GuruFocus

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-15-2019